Overall , results indicate that conversion from previous strong opioids to tapentadol ER ( 50-250 mg twice daily ) was successful and resulted in safe and effective pain control with improved gastrointestinal tolerability versus morphine SR in patients with moderate to severe cancer-related pain that was well-controlled on their previous opioid .